Previous Close | 1.5200 |
Open | 1.5500 |
Bid | 1.3800 x 800 |
Ask | 1.4800 x 1000 |
Day's Range | 1.4500 - 1.5600 |
52 Week Range | 1.3300 - 3.2900 |
Volume | |
Avg. Volume | 13,070 |
Market Cap | 15.057M |
Beta (5Y Monthly) | 1.34 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.9700 |
Earnings Date | Mar 27, 2024 - Apr 01, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for COCP
Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash., March 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has received Pre-Investigational New Drug (Pre-IND) feedback from the U.S. Food and Drug Administration (FDA) regarding CC-42344 as a potential oral treatment for pandemic and seasonal influenza A. A Pre-IND review provides the opportunity to obtain FDA guidance and clarificatio
LOS ANGELES, CA / ACCESSWIRE / March 5, 2024 / Planet MicroCap today published a new Video Interview with Jim Martin, Co-CEO and CFO, from Cocrystal Pharma, Inc. (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel ...
By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT On January 8, 2024, Cocrystal Pharma (NASDAQ:COCP) released a new investor presentation which can be found here . On January 4, 2024, Cocrystal Pharma provided an update on the clinical development of its oral first-in-class pan-norovirus and pan-coronavirus dual protease inhibitor CDI-988 and its oral PB2 inhibitor CC-42344 for